Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

Our Discoveries

Near-infrared compounds for visualizing enzymatic activity in living organisms

New fluorescent probes developed that can help clinicians pinpoint cancer metastases

New chemical compounds developed by CCR researchers and clinicians are safe and highly effective in fluorescently highlighting microscopic metastases. The new compounds could have great utility in complex living systems based on experiments done in mouse models of metastatic human ovarian cancer.

Stem cell transplant after CAR T-cell therapy effective for young leukemia patients

In a clinical trial, CCR physician-scientists found that long-term survival for young patients with B-cell acute lymphoblastic leukemia was significantly better for those who received CD19-CAR T-cell therapy followed by a stem cell transplant. As a result of these findings, use of stem cell transplant is now recommended following CAR T-cell therapy.

New tool predicts which treatments may work best in cancer patients

A new precision oncology software tool, called SELECT, analyzes tumor transcriptomics data to predict which therapies are most beneficial for an individual patient. When applied to data from over 30 different clinical trials, SELECT was predictive of patient responses to targeted and immune therapies in about 80 percent of the trial datasets.

Drug combination leads to durable responses in patients with small cell lung cancer

Relapse after chemotherapy is common among patients with small cell neuroendocrine cancers, including small cell lung cancer. In a new clinical study, CCR scientists found a combination of berzosertib and topotecan led to durable tumor responses in patients with these cancers.

Engineered myeloid cells have promise as a potential treatment for metastatic cancer

A team led by Rosandra N. Kaplan, M.D., Investigator in the Pediatric Oncology Branch, genetically engineered immune cells, called myeloid cells, to deliver an anti-cancer signal to organs where cancer may spread. The results of the treatment, reported in Cell, shrank tumors and prevented metastasis in mice.

FDA grants orphan drug designation to PRGN-2012 for recurrent respiratory papillomatosis

The Food and Drug Administration has granted orphan drug designation to PRGN-2012 immunotherapy for use in patients with recurrent respiratory papillomatosis.

High magnification micrograph of a clear cell renal cell carcinoma

Combination therapy in patients with advanced kidney cancer found to be highly effective

A phase III international clinical trial that tested the combination therapy of nivolumab and cabozantinib in patients with advanced, untreated renal-cell carcinoma yielded promising results.

Hotspots for DNA damage and repair in neurons identified

Researchers have pinpointed hotspots along the genome of neurons where endogenous, or internally driven, DNA breaks and repair accumulate. If the breaks are not repaired rapidly, they can lead to neuron dysfunction, degeneration and death.

New finding reveals how some cancers gain or lose chromosomes

Some cancers have an abnormal number of chromosomes, and patients with these cancers tend to have a worse prognosis. CCR researchers have uncovered how overexpression of just one protein can cause these chromosome abnormalities – hinting at a mechanism that could be therapeutically targeted.

Drug lessens symptoms of severe chronic graft-versus-host disease

About half of patients who receive allogeneic stem cell transplants, a treatment for blood cancer, develop a difficult-to-treat condition called chronic graft-versus-host disease (cGVHD). CCR investigators have found that pomalidomide, an immune-modulating drug, can reduce symptoms in patients with severe cases of cGVHD.

Breadcrumb

Our Discoveries